Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. - Abstract - Europe PMC
PDF) Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
Interim results from a large multinational extension trial (guardian <sup>â—¢</sup>2) using turoctocog alfa for p
Protocol Phase 1 Template
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
Full article: Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden
CLINICAL STUDY PROTOCOL
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors | PLOS ONE
Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa - Santagostino - 2014 - Haemophilia - Wiley Online Library
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Spotlight on pomalidomide: could less be more? | Leukemia
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
Clinical Trials - Cue Biopharma
